COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02670083




Registration number
NCT02670083
Ethics application status
Date submitted
28/01/2016
Date registered
1/02/2016
Date last updated
16/07/2020

Titles & IDs
Public title
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
Scientific title
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease.
Secondary ID [1] 0 0
2015-003034-27
Secondary ID [2] 0 0
BN29552
Universal Trial Number (UTN)
Trial acronym
CREAD
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Crenezumab
Treatment: Drugs - Placebo

Placebo Comparator: Placebo - Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.

Experimental: Crenezumab - Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.


Treatment: Drugs: Crenezumab
Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.

Treatment: Drugs: Placebo
Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline to Week 105 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score - The CDR-SB rates impairment in 6 categories (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment = 0, questionable impairment = 0.5 and mild, moderate and severe impairment = 1, 2 and 3 respectively. The score range is from 0 to 18 with a high score indicating a high disease severity. The difference in mean change from Baseline to Week 105 between Crenezumab and Placebo treated participants was estimated. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline for this primary endpoint. Data after 29 January 2019 are censored for the primary and secondary efficacy analyses to avoid potential biases due to investigators, participants, raters, etc. being potentially influenced by early closure of the study due to lack of efficacy.
Timepoint [1] 0 0
Baseline, Week 105
Secondary outcome [1] 0 0
Change From Baseline to Week 105 on Cognition, as Assessed by Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) (Subscale) 13 (ADAS-Cog-13) - The ADAS-Cog-13 assesses multiple cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. Most of these are assessed by tests although some are rated by the clinician on a 5-point scale. The ADAS-Cog-13 is the ADAS-Cog-11 with 2 further items: delayed word recall and total digit cancellation. The score range for ADAS-Cog-13 is from 0 to 85 with high scores representing severe dysfunction. The difference in mean change from Baseline to Week 105 between Crenezumab and Placebo treated participants was estimated. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region, and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline.
Timepoint [1] 0 0
Baseline, Week 105
Secondary outcome [2] 0 0
Change From Baseline to Week 105 on Cognition, as Assessed by Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) (Subscale) 11 (ADAS-Cog-11) - The ADAS-Cog-11 assesses multiple cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. Most of these are assessed by tests although some are rated by the clinician on a 5-point scale. The score range for ADAS-Cog-11 is from 0 to 70 with high scores representing severe dysfunction. The difference in mean change from Baseline to Week 105 between Crenezumab and Placebo treated participants was estimated. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region, and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline.
Timepoint [2] 0 0
Baseline, Week 105
Secondary outcome [3] 0 0
Change From Baseline to Week 105 on Severity of Dementia, Assessed Using the CDR-Global Score (CDR-GS) - The CDR-GS represents a semi-structured interview which rates impairment in 6 categories (memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care) on a 5-point scale in which CDR 0 = no dementia and CDR 0.5, 1, 2 or 3 = questionable, mild, moderate or severe dementia respectively. The range in scores for the CDR-GS is from 0 to 3 and a high score on the CDR-GS would indicate a high disease severity. The difference in mean change from Baseline to Week 105 between Crenezumab and Placebo treated participants was estimated. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region, and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline.
Timepoint [3] 0 0
Baseline, Week 105
Secondary outcome [4] 0 0
Change From Baseline to Week 105 on Severity of Dementia, Assessed Using the Mini Mental State Evaluation (MMSE) - The MMSE is a set of standardized questions used to evaluate possible cognitive impairment and help stage the severity level of this impairment. The questions target 6 areas: orientation, registration, attention, short-term recall, language and constructional praxis/visuospatial abilities. The scores on the MMSE range from 0 to 30, with higher scores indicating better function. The difference in mean change from Baseline to Week 105 between Crenezumab and Placebo treated participants was estimated. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region, and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline.
Timepoint [4] 0 0
Baseline, Week 105
Secondary outcome [5] 0 0
Change From Baseline to Week 105 on Function as Assessed by the ADCS-ADL Total Score - The ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living) is the scale most widely used to assess functional outcomes in participants with AD. The ADCS-ADL covers both basic ADL (e.g., eating and toileting) and more complex 'instrumental' ADL or iADL (e.g., using the telephone, managing finances and preparing a meal). The ADCS-ADL consists of 23 questions with a score range of 0 to 78 where a higher score represents better function. The difference in mean change from Baseline to Week 105 between Crenezumab and Placebo treated participants was estimated. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region, and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline.
Timepoint [5] 0 0
Baseline, Week 105
Secondary outcome [6] 0 0
Change From Baseline to Week 105 on Function as Assessed by the ADCS-instrumental (ADCS-iADL) Subscore - The ADCS-iADL (Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living) measures activities such as using the telephone, managing finances and preparing a meal. The ADCS-iADL consists of 16 questions with a score range of 0 to 56 where a higher score represents better function. The difference in mean change from Baseline to Week 105 between Crenezumab and Placebo treated participants was estimated. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region, and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline.
Timepoint [6] 0 0
Baseline, Week 105
Secondary outcome [7] 0 0
Change From Baseline to Week 105 on a Measure of Dependence Derived From the ADCS-ADL Score - The ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living) is the scale most widely used to assess functional outcomes in participants with AD. The ADCS-ADL covers both basic ADL (e.g., eating and toileting) and more complex 'instrumental' ADL or iADL (e.g., using the telephone, managing finances and preparing a meal). The ADCS-ADL consists of 23 questions with a score range of 0 to 78 where a higher score represents better function. The difference in mean change from Baseline to Week 105 between Crenezumab and Placebo treated participants was estimated. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region, and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline.
Timepoint [7] 0 0
Baseline, Week 105
Secondary outcome [8] 0 0
Change From Baseline to Week 105 Assessed Using the Neuropsychiatric Inventory Questionnaire (NPI-Q) - The NPI-Q is an informant-based instrument that evaluates 12 neuropsychiatric disturbances common in dementia: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavioral disturbances and appetite and eating abnormalities. The severity of each neuropsychiatric symptom is rated on a 3-point scale (mild, moderate and marked). The total severity score range is from 0 to 36 with higher scores representing higher severity. The difference in mean change from Baseline to Week 105 between Crenezumab and Placebo treated participants was estimated. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region, and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline.
Timepoint [8] 0 0
Baseline, Week 105
Secondary outcome [9] 0 0
Quality of Life-Alzheimer's Disease (QoL-AD) Scale Score - The QoL-AD (Quality of Life - Alzheimer's Disease) scale assesses QoL in participants who have dementia. The QoL-AD consists of 13 items covering aspects of participants' relationships with friends and family, physical condition, mood, concerns about finances and overall assessment of QoL. Items are rated on 4-point Likert-type scales ranging from 1 [poor] to 4 [excellent]. The score range is from 13 to 52, with higher scores indicating a better QoL. The difference in mean change from Baseline to Week 105 between Crenezumab and Placebo treated participants was estimated. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region, and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline.
Timepoint [9] 0 0
Baseline up to Week 105
Secondary outcome [10] 0 0
Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) Scale Score - The ZCI-AD is a modified version of the Zarit Burden Interview, which was originally designed to reflect the stresses experienced by caregivers of people with dementia. This modified version includes slight modifications in item and title wording (e.g., removal of "your relative" to refer directly to the patient, removal of "burden" from title) and the use of 11-point numerical rating scales. The ZCI-AD scale consists of a total of 30 items. Total scores will be calculated with a total score range from 0 to 300 (higher scores indicate a higher burden on the caregiver). The difference in mean change from Baseline to Week 105 between Crenezumab and Placebo treated participants was estimated. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region, and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline.
Timepoint [10] 0 0
Baseline up to Week 105
Secondary outcome [11] 0 0
EQ-5D Questionnaire Domain Score for Participants - The EQ-5D is a standardized measure of health status designed to provide a simple generic measure of health for clinical and economic appraisal. It is broadly applicable across a wide range of health conditions and treatment. The EQ-5D assesses five domains to provide a health state index. These are anxiety/depression, pain/discomfort, usual activities, mobility, and self-care. The scores on the EQ-5D ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). The difference in mean change from Baseline to Week 105 between Crenezumab and Placebo treated participants was estimated. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region, and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline.
Timepoint [11] 0 0
Baseline up to Week 105
Secondary outcome [12] 0 0
EQ-5D Questionnaire Domain Score for Caregivers - The EQ-5D is a standardized measure of health status designed to provide a simple generic measure of health for clinical and economic appraisal. It is broadly applicable across a wide range of health conditions and treatment. The EQ-5D assesses five domains to provide a health state index. These are anxiety/depression, pain/discomfort, usual activities, mobility, and self-care. The scores on the EQ-5D ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). The difference in mean change from Baseline to Week 105 between Crenezumab and Placebo treated participants was estimated. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region, and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline.
Timepoint [12] 0 0
Baseline up to Week 105
Secondary outcome [13] 0 0
Percentage of Participants With Adverse Event (AEs) and Serious Adverse Event (SAEs) - An Adverse Event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Timepoint [13] 0 0
Baseline up until 16 weeks after the last dose of study drug (up to 117 weeks).
Secondary outcome [14] 0 0
Percentage of Participants With Anti-Crenezumab Antibodies - Participants were considered positive or negative for ADA based on their baseline and post-baseline sample results. The number and percentage of participants with confirmed positive ADA levels were determined for Crenezumab and Placebo groups. The prevalence of ADA at baseline was calculated as the proportion of participants with confirmed positive ADA levels at baseline relative to the total number of participants with a sample available at baseline. The incidence of treatment-emergent ADAs was determined as the proportion of participants with confirmed post-baseline positive ADAs relative to the total number of participants that had at least one post-baseline sample available for ADA analysis.
Timepoint [14] 0 0
Baseline up to Week 105
Secondary outcome [15] 0 0
Serum Concentration of Crenezumab - Serum concentration data for Crenezumab will be tabulated and summarized. Descriptive summary statistics will include the arithmetic mean and SD. Since a sparse PK sampling design is being used, population (non-linear mixed-effects) modeling will be used to analyze the dose concentration-time data of crenezumab. Information from other clinical studies may be incorporated to establish the PK model. Please note that Post-dose samples were not collected at Weeks 37 and 105.
Timepoint [15] 0 0
Pre-infusion (0 hour), 60-90 minutes post-infusion on Day 1 Week 1 and on Week 25; Weeks 13, 37 (Pre-dose), 53, 77 and 105 (infusion length = as per the Pharmacy Manual)
Secondary outcome [16] 0 0
Plasma Amyloid Beta (Abeta) 40 Concentrations - Plasma Abeta 40 concentrations will be measured over time and descriptive summary statistics will include the arithmetic mean and SD. Please note that a Post-dose sample was only collected at Week 13.
Timepoint [16] 0 0
Week 1 Day 1; Weeks 13, 25, 53, 77 and 105
Secondary outcome [17] 0 0
Plasma Amyloid Beta (Abeta) 42 Concentrations - Plasma Abeta 42 concentrations will be measured over time and descriptive summary statistics will include the arithmetic mean and SD. Please note that a Post-dose sample was only collected at Week 13.
Timepoint [17] 0 0
Week 1 Day 1; Weeks 13, 25, 53, 77 and 105
Secondary outcome [18] 0 0
Percentage Change From Baseline to Week 105 in Whole Brain Volume as Determined by Magnetic Resonance Imaging (MRI) - Percentage Change in Whole Brain Volume will be measured over time and descriptive summary statistics will include the arithmetic mean, median, range, SD, and coefficient of variation, as appropriate. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region, and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline.
Timepoint [18] 0 0
Baseline, Week 105
Secondary outcome [19] 0 0
Percentage Change From Baseline to Week 105 in Ventricle Volume as Determined by Magnetic Resonance Imaging (MRI) - Percentage Change in Ventricle Volume will be measured over time and descriptive summary statistics will include the arithmetic mean, median, range, SD, and coefficient of variation, as appropriate. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region, and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline.
Timepoint [19] 0 0
Baseline, Week 105
Secondary outcome [20] 0 0
Percentage Change From Baseline to Week 105 in Hippocampal Volume as Determined by Magnetic Resonance Imaging (MRI) - Percentage Change in Hippocampal Volume will be measured over time and descriptive summary statistics will include the arithmetic mean, median, range, SD, and coefficient of variation, as appropriate. Mixed model repeated measures (MMRMs) adjusting for disease severity, APOEe4 status, geographic region, and the use or non-use of anti-dementia medications at baseline were used to estimate the mean change from baseline.
Timepoint [20] 0 0
Baseline, Week 105

Eligibility
Key inclusion criteria
- Weight between 40 and 120 kilograms (Kg) inclusive

- Availability of a person (referred to as the "caregiver") who in the investigator's
judgment:

- Has frequent and sufficient contact with the participant to be able to provide
accurate information regarding the participant's cognitive and functional abilities,
agrees to provide information at clinic visits (which require partner input for scale
completion), signs the necessary consent form, and has sufficient cognitive capacity
to accurately report upon the participant's behavior and cognitive and functional
abilities

- Fluency in the language of the tests used at the study site

- Adequate visual and auditory acuity, in the investigator's judgment, sufficient to
perform the neuropsychological testing (eye glasses and hearing aids are permitted)

- Evidence of the AD pathological process, by a positive amyloid assessment either on
cerebrospinal fluid (CSF) amyloid beta 1-42 levels as measured on the Elecsys
beta-amyloid(1-42) test system or amyloid PET scan by qualitative read by the
core/central PET laboratory

- Demonstrated abnormal memory function at screening (up to 4 weeks before screening
begins) or screening (FCSRT cueing index =<0.67 AND free recall =<27)

- Screening mini mental state examination (MMSE) score of greater than or equal to (>=)
22 points and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 or 1.0

- Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical
criteria for probable AD dementia or prodromal AD (consistent with the NIAAA
diagnostic criteria and guidelines for mild cognitive impairment (MCI)

- If receiving symptomatic AD medications, the dosing regimen must have been stable for
3 months prior to screening

- Participant must have completed at least 6 years of formal education after the age of
5 years
Minimum age
50 Years
Maximum age
85 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Any evidence of a condition other than AD that may affect cognition such as other
dementias, stroke, brain damage, autoimmune disorders (e.g. multiple sclerosis) or
infections with neurological sequelae.

- History of major psychiatric illness such as schizophrenia or major depression (if not
considered in remission)

- At risk of suicide in the opinion of the investigator

- Any abnormal MRI findings, such as presence of cerebral vascular pathology, cortical
stroke, etc or inability to tolerate MRI procedures or contraindication to MRI

- Unstable or clinically significant cardiovascular (e.g., myocardial infarction),
kidney or liver disease

- Uncontrolled hypertension

- Screening hemoglobin A1c (HbA1C) >8%

- Poor peripheral venous access

- History of cancer except:

If considered to be cured or If not being actively treated with anti-cancer therapy or
radiotherapy

- Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric, human, or humanized antibodies or fusion proteins

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA,VIC,WA
Recruitment hospital [1] 0 0
The Queen Elizabeth Hospital; Neurology - Woodville
Recruitment hospital [2] 0 0
Caulfield Hospital; Aged Psychiatry Research Unit - Caulfield
Recruitment hospital [3] 0 0
Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre - Heidelberg West
Recruitment hospital [4] 0 0
Neurodegenerative Disorders Research; Neurology - West Perth
Recruitment postcode(s) [1] 0 0
5011 - Woodville
Recruitment postcode(s) [2] 0 0
3162 - Caulfield
Recruitment postcode(s) [3] 0 0
3081 - Heidelberg West
Recruitment postcode(s) [4] 0 0
6005 - West Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Maine
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Mississippi
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Oklahoma
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
Texas
Country [20] 0 0
United States of America
State/province [20] 0 0
Virginia
Country [21] 0 0
United States of America
State/province [21] 0 0
Wisconsin
Country [22] 0 0
Austria
State/province [22] 0 0
Linz
Country [23] 0 0
Belgium
State/province [23] 0 0
Gent
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Sofia
Country [25] 0 0
Canada
State/province [25] 0 0
British Columbia
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario
Country [27] 0 0
Canada
State/province [27] 0 0
Quebec
Country [28] 0 0
Costa Rica
State/province [28] 0 0
San Jose
Country [29] 0 0
Costa Rica
State/province [29] 0 0
San José
Country [30] 0 0
Croatia
State/province [30] 0 0
Zagreb
Country [31] 0 0
Czechia
State/province [31] 0 0
Hradec Králové
Country [32] 0 0
Czechia
State/province [32] 0 0
Praha
Country [33] 0 0
Denmark
State/province [33] 0 0
Aarhus N
Country [34] 0 0
Denmark
State/province [34] 0 0
København Ø
Country [35] 0 0
Finland
State/province [35] 0 0
Tampere
Country [36] 0 0
Finland
State/province [36] 0 0
Turku
Country [37] 0 0
France
State/province [37] 0 0
Bobigny
Country [38] 0 0
France
State/province [38] 0 0
Bron
Country [39] 0 0
France
State/province [39] 0 0
Montpellier
Country [40] 0 0
France
State/province [40] 0 0
Paris
Country [41] 0 0
France
State/province [41] 0 0
Poitiers
Country [42] 0 0
France
State/province [42] 0 0
Strasbourg
Country [43] 0 0
France
State/province [43] 0 0
Toulouse
Country [44] 0 0
Germany
State/province [44] 0 0
München
Country [45] 0 0
Germany
State/province [45] 0 0
Münster
Country [46] 0 0
Germany
State/province [46] 0 0
Nürnberg
Country [47] 0 0
Germany
State/province [47] 0 0
Rostock
Country [48] 0 0
Germany
State/province [48] 0 0
Ulm
Country [49] 0 0
Germany
State/province [49] 0 0
Westerstede
Country [50] 0 0
Germany
State/province [50] 0 0
Witten
Country [51] 0 0
Hong Kong
State/province [51] 0 0
Hong Kong
Country [52] 0 0
Hungary
State/province [52] 0 0
Budapest
Country [53] 0 0
Hungary
State/province [53] 0 0
Nyíregyháza
Country [54] 0 0
Hungary
State/province [54] 0 0
Szeged
Country [55] 0 0
Hungary
State/province [55] 0 0
Tatabánya
Country [56] 0 0
Hungary
State/province [56] 0 0
VAC
Country [57] 0 0
Italy
State/province [57] 0 0
Lazio
Country [58] 0 0
Italy
State/province [58] 0 0
Liguria
Country [59] 0 0
Italy
State/province [59] 0 0
Lombardia
Country [60] 0 0
Italy
State/province [60] 0 0
Umbria
Country [61] 0 0
Japan
State/province [61] 0 0
Hiroshima
Country [62] 0 0
Japan
State/province [62] 0 0
Kyoto
Country [63] 0 0
Japan
State/province [63] 0 0
Mie
Country [64] 0 0
Japan
State/province [64] 0 0
Nagano
Country [65] 0 0
Japan
State/province [65] 0 0
Niigata
Country [66] 0 0
Japan
State/province [66] 0 0
Okayama
Country [67] 0 0
Japan
State/province [67] 0 0
Tokyo
Country [68] 0 0
Korea, Republic of
State/province [68] 0 0
Gwangju
Country [69] 0 0
Korea, Republic of
State/province [69] 0 0
Incheon
Country [70] 0 0
Korea, Republic of
State/province [70] 0 0
Seoul
Country [71] 0 0
Lithuania
State/province [71] 0 0
Vilnius
Country [72] 0 0
Mexico
State/province [72] 0 0
Culiacan
Country [73] 0 0
Mexico
State/province [73] 0 0
Monterrey
Country [74] 0 0
Mexico
State/province [74] 0 0
Saltillo
Country [75] 0 0
Poland
State/province [75] 0 0
Bialystok
Country [76] 0 0
Poland
State/province [76] 0 0
Poznan
Country [77] 0 0
Poland
State/province [77] 0 0
Siemianowice Slaskie
Country [78] 0 0
Poland
State/province [78] 0 0
Warszawa
Country [79] 0 0
Portugal
State/province [79] 0 0
Amadora
Country [80] 0 0
Portugal
State/province [80] 0 0
Loures
Country [81] 0 0
Russian Federation
State/province [81] 0 0
Kazan
Country [82] 0 0
Russian Federation
State/province [82] 0 0
Moscow
Country [83] 0 0
Russian Federation
State/province [83] 0 0
Saratov
Country [84] 0 0
Russian Federation
State/province [84] 0 0
St Petersburg
Country [85] 0 0
Russian Federation
State/province [85] 0 0
St. Petersburg
Country [86] 0 0
Slovenia
State/province [86] 0 0
Maribor
Country [87] 0 0
Spain
State/province [87] 0 0
Barcelona
Country [88] 0 0
Spain
State/province [88] 0 0
Caceres
Country [89] 0 0
Spain
State/province [89] 0 0
Cantabria
Country [90] 0 0
Spain
State/province [90] 0 0
Navarra
Country [91] 0 0
Spain
State/province [91] 0 0
Salamanca
Country [92] 0 0
Spain
State/province [92] 0 0
Albacete
Country [93] 0 0
Spain
State/province [93] 0 0
Burgos
Country [94] 0 0
Spain
State/province [94] 0 0
Madrid
Country [95] 0 0
Spain
State/province [95] 0 0
Malaga
Country [96] 0 0
Spain
State/province [96] 0 0
Murcia
Country [97] 0 0
Spain
State/province [97] 0 0
Valencia
Country [98] 0 0
Spain
State/province [98] 0 0
Zaragoza
Country [99] 0 0
Sweden
State/province [99] 0 0
Malmö
Country [100] 0 0
Sweden
State/province [100] 0 0
Mölndal
Country [101] 0 0
Sweden
State/province [101] 0 0
Stockholm
Country [102] 0 0
Switzerland
State/province [102] 0 0
Basel
Country [103] 0 0
Turkey
State/province [103] 0 0
Ankara
Country [104] 0 0
Turkey
State/province [104] 0 0
Eskisehir
Country [105] 0 0
Turkey
State/province [105] 0 0
Istanbul
Country [106] 0 0
Turkey
State/province [106] 0 0
Samsun
Country [107] 0 0
Ukraine
State/province [107] 0 0
KIEV Governorate
Country [108] 0 0
Ukraine
State/province [108] 0 0
Kiev
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Blackburn
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Chertsey
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Coventry
Country [112] 0 0
United Kingdom
State/province [112] 0 0
London
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Manchester
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Newcastle Upon Tyne
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the
efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab
or placebo every 4 weeks (Q4W) for 100 weeks. The final efficacy and safety assessment will
be performed 52 weeks after the last crenezumab dose. Participants will then have the option
to enter the Open Label Extension (OLE) study if eligible. Participants who do not enter the
OLE study will have additional follow-up visits at 16 and 52 weeks after the last dose,
primarily for safety and also for limited efficacy assessments.
Trial website
https://clinicaltrials.gov/show/NCT02670083
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT02670083